Chief Scientific Officer of Lilly: A Major Breakthrough in Alzheimer's Disease is Coming, Like a Weight Loss Drug
芊芊551
发表于 2023-11-7 18:45:35
321
0
0
Dr. Daniel Skovronsky, Chief Scientific Officer of Lilly, the world's most valuable pharmaceutical company, stated with extreme optimism that a major breakthrough in the treatment of Alzheimer's disease is imminent and that the drug being developed may become the next hot spot similar to the weight loss miracle drug "GLP-1".
CandyLake.com 系信息发布平台，仅提供信息存储空间服务。
声明：该文观点仅代表作者本人，本文不代表CandyLake.com立场，且不构成建议，请谨慎对待。
声明：该文观点仅代表作者本人，本文不代表CandyLake.com立场，且不构成建议，请谨慎对待。
转播
猜你喜欢
- The review results of Supermicro Computer did not find any inappropriate behavior and decided to replace the Chief Financial Officer
- OpenAI poaching cryptocurrency company Coinbase hires its first Chief Marketing Officer
- OpenAI hires former Coinbase executive as Chief Marketing Officer
- Alphabet Chief Investment Officer: Google's biggest bet is to introduce artificial intelligence into search
- Former head of user development department at Jiyue Motors joins Starbucks as Chief Growth Officer
- Eli Lilly's Alzheimer's disease therapy, Minolta (Donaimab Injection), has been approved in China
- Eli Lilly's Alzheimer's disease treatment with donentinumab injection approved
- Eli Lilly's Alzheimer's disease therapy, Minolta (Donaimab Injection), has been approved in China
- Boeing appoints Chief Communications Officer
- Eli Lilly's new Alzheimer's disease drug launched: annual drug cost exceeds $30000, Pfizer Roche is expanding its strategy
